Table 3.
Investigator and/or expert assessment | PFI (N = 54) |
Overall response (N = 54) | |
<6 months (n = 40) | ≥6 months (n = 14) | ||
CR, n (%) | 0 | 0 | 0 |
PR, n (%) | 7 (17.5) | 7 (50.0) | 14 (25.9) |
SD, n (%) | 11 (27.5) | 4 (28.6) | 15 (27.8) |
PD, n (%) | 15 (37.5) | 3 (21.4) | 18 (33.3) |
UK, n (%) | 7 (17.5) | 0 | 7 (13.0) |
ITT, intention-to-treat; EE, efficacy evaluable; PFI, progression-free interval; CR, complete response, PR, partial response; SD, stable disease; PD, progressive disease; UK, unknown.